PUBLIC COMPANY
saveWindward Bio AG
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Windward Bio hits Nasdaq with $175M IPO, plus another $50M from SanofiWindward Bio, a biotech developing drugs for respiratory diseases, made its public debut after putting together $175 million in its IPO. The company began trading Friday with an initial share price…endpoints · 3d ago
- Windward nets $175M IPO, bringing 2026 biotech debuts to 35Windward Bio’s public debut brings this year’s IPO count well above the sluggish total of eight in 2025.biospace · 3d ago
- Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’Windward Bio’s IPO has blown to exactly the spot the Swiss biotech had been aiming for, bringing in $225 million to fund a pair of respiratory drugs licensed from China.fiercebiotech · 4d ago
- Windward prices $175M IPO to advance China-licensed lung drugsThe Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.biopharma_dive · 4d ago
- Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaWindward Bio is sailing toward the public markets with the aim of raising over $200 million in proceeds to fund two respiratory drugs licensed from China.fiercebiotech · 8d ago
- Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listingLycia Therapeutics went public with an upsized $317.5 million IPO on Friday, while immunology-focused Windward Bio is hoping to catch the same tailwinds.fiercebiotech · 22d ago
- Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&DA 2-year-old European biotech with two clinical-stage assets from China is the latest to attempt an initial public offering in the US. Basel-based Windward Bio submitted its cards for a Nasdaq ...endpoints · 24d ago
- Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…endpoints · 2mo ago
- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...endpoints · 6mo ago
comments(0)
5-min edit window · permanent after that